RU2019133594A3 - - Google Patents

Download PDF

Info

Publication number
RU2019133594A3
RU2019133594A3 RU2019133594A RU2019133594A RU2019133594A3 RU 2019133594 A3 RU2019133594 A3 RU 2019133594A3 RU 2019133594 A RU2019133594 A RU 2019133594A RU 2019133594 A RU2019133594 A RU 2019133594A RU 2019133594 A3 RU2019133594 A3 RU 2019133594A3
Authority
RU
Russia
Application number
RU2019133594A
Other versions
RU2019133594A (ru
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of RU2019133594A publication Critical patent/RU2019133594A/ru
Publication of RU2019133594A3 publication Critical patent/RU2019133594A3/ru

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D475/00Heterocyclic compounds containing pteridine ring systems
    • C07D475/02Heterocyclic compounds containing pteridine ring systems with an oxygen atom directly attached in position 4
    • C07D475/04Heterocyclic compounds containing pteridine ring systems with an oxygen atom directly attached in position 4 with a nitrogen atom directly attached in position 2
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52Purines, e.g. adenine
    • A61K31/522Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/02Nutrients, e.g. vitamins, minerals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06Antianaemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Nutrition Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
RU2019133594A 2017-03-31 2018-03-28 Кристаллическая натриевая соль 5-метил-(6s)-тетрагидрофолиевой кислоты RU2019133594A (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP17164349 2017-03-31
EP17164349.7 2017-03-31
PCT/EP2018/057900 WO2018178141A1 (en) 2017-03-31 2018-03-28 Crystalline sodium salt of 5-methyl-(6s)-tetrahydrofolic acid

Publications (2)

Publication Number Publication Date
RU2019133594A RU2019133594A (ru) 2021-04-30
RU2019133594A3 true RU2019133594A3 (ru) 2021-07-21

Family

ID=58464443

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2019133594A RU2019133594A (ru) 2017-03-31 2018-03-28 Кристаллическая натриевая соль 5-метил-(6s)-тетрагидрофолиевой кислоты

Country Status (9)

Country Link
US (2) US11185545B2 (ru)
EP (1) EP3609894A1 (ru)
JP (1) JP7285785B2 (ru)
KR (1) KR102665004B1 (ru)
CN (1) CN110475778A (ru)
AU (1) AU2018246265B2 (ru)
CA (1) CA3058287A1 (ru)
RU (1) RU2019133594A (ru)
WO (1) WO2018178141A1 (ru)

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5124452A (en) 1978-07-10 1992-06-23 Bioresearch S.P.A. Process for producing d,1-5-methyltetrahydrofolic acid and its salts
IT1229517B (it) 1989-01-31 1991-09-03 Bioresearch Spa Impiego di acido 5-metiltetraidrofolico, di acido 5 formiltetraidrofolico, e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato adatte ad essere impiegate nella terapia dei disordini depressivi e composizioni farmaceutiche relative.
CH686369A5 (de) 1994-05-09 1996-03-15 Eprova Ag Stabile kristalline (6S)- und (6R)-Tetrahydrofolseure.
ZA968485B (en) 1995-11-01 1997-05-20 Lonza Ag Process for preparing nicotinamide
CH689831A5 (de) 1995-11-07 1999-12-15 Eprova Ag Stabile kristalline Tetrahydrofolsaeure-Salze.
CH693255A5 (de) * 1997-06-13 2003-05-15 Eprova Ag Verwendung von Tetrahydrofolaten in der natürlichenstereoisomeren Form zur Herstellung einer pharmazeutischenZubereitung geeignet zur Beeinflussung des Homocystein-Spiegels.
CH693905A5 (de) 1999-04-15 2004-04-15 Eprova Ag Stabile kristalline Salze von 5-Methyltetrahydrofolsäure.
AU2008351242B2 (en) 2008-02-20 2012-12-20 Gnosis S.P.A. Folates, compositions and uses thereof
WO2013025203A1 (en) * 2011-08-16 2013-02-21 Watson Laboratories, Inc. Resolution of tetrahydrofolic acid derivatives
ITMI20111808A1 (it) * 2011-10-05 2013-04-06 Ati S R L Composizione alimentare priva di glutine e prodotti alimentari con essa preparati
WO2013107236A1 (zh) * 2012-01-20 2013-07-25 连云港金康和信药业有限公司 (6s)-5-甲基四氢叶酸盐晶型及其制备方法
CN104557937B (zh) * 2012-01-20 2017-03-08 连云港金康和信药业有限公司 (6s)‑5‑甲基四氢叶酸盐晶型及其制备方法
US20160207925A1 (en) * 2013-12-31 2016-07-21 Gianni Fracchia L-methylfolate salt preparations, medicaments, and nutritional supplements comprising such salts thereof
WO2015193778A1 (en) * 2014-06-16 2015-12-23 Mylan Laboratories Ltd. Crystalline form of levomefolate calcium

Also Published As

Publication number Publication date
AU2018246265B2 (en) 2022-07-07
KR20190136029A (ko) 2019-12-09
US20200030333A1 (en) 2020-01-30
US20220016121A1 (en) 2022-01-20
CA3058287A1 (en) 2018-10-04
US11185545B2 (en) 2021-11-30
KR102665004B1 (ko) 2024-05-09
WO2018178141A1 (en) 2018-10-04
EP3609894A1 (en) 2020-02-19
JP7285785B2 (ja) 2023-06-02
RU2019133594A (ru) 2021-04-30
JP2020512383A (ja) 2020-04-23
AU2018246265A1 (en) 2019-11-14
CN110475778A (zh) 2019-11-19

Similar Documents

Publication Publication Date Title
BR122021024395A2 (ru)
BR122022003522A2 (ru)
BR122022025811B8 (ru)
BR122021000189A2 (ru)
BR112019008823A2 (ru)
BR112020006084A8 (ru)
BR122021014832A2 (ru)
RU2019134064A3 (ru)
BR202018014992U2 (ru)
RU2019133594A3 (ru)
BR102017023327A2 (ru)
BR202017021228U2 (ru)
BR202017020981U2 (ru)
BE2017C035I2 (ru)
BR202017017068U2 (ru)
BR202017016984U2 (ru)
BR202017016924U2 (ru)
BR102017015495A2 (ru)
BR102017015250A2 (ru)
BR102017014430A2 (ru)
BR202017012548U2 (ru)
BR202017011220U2 (ru)
BR202017010814U2 (ru)
BR202017010373U2 (ru)
BR202017009870U2 (ru)